Adipromin is not a stimulant or appetite suppressant. It does not interfere with absorption of fat or sugar, nor does it create a sense of fullness. Preclinical research indicates a dual mode of action:

• Modulation of adipogenesis and lipolysis. Adipromin has been shown in preclinical research to inhibit lipid accumulation in adipocytes, slowing differentiation and maturation of adipocytes, and reducing intracellular triglyceride content. These actions are thought to be due to the demonstrated down-regulation of transcription factors PPAR‐gamma and C/EBP.†*

• Increases Resting Energy Expenditure (REE). Adipromin has been shown in two preclinical animal studies† and one human clinical trial to increase resting energy expenditure.* The underlying mechanisms driving this increased metabolic activity have been elucidated and include notable increases in the production level of thermogenic markers (AMPKα, PGC1α and UCP1) and lipolytic (HSL) proteins.†

CLINICAL EFFICACY
The clinical efficacy of Adipromin for weight loss has been demonstrated in two randomized, double-blind, placebo-controlled clinical trials (RCTs), published in well-respected medical journals.*

The exemplary second RCT of Adipromin—published in a top-tier medical journal—was conducted in healthy overweight subjects (n=140). The 16-week study compared the use of Adipromin in conjunction with an 1800 kcal/day diet and walking plan (30 min 5 times per week) to a placebo with the same diet and walking plan.

Dixit K, et al. Efficacy of a novel herbal formulation for weight loss demonstrated in a 16-week randomized, double-blind, placebo-controlled clinical trial with healthy overweight adults. Diabetes Obes Metab. 2018;20(11):2633-2641. doi:10.1111/dom.13443

• At the end of the study, subjects taking Adipromin showed significant reductions in body weight (-11.82 pounds vs. -1.92 pounds; p < 0.0001) and BMI (2.05 kg vs. 0.34 kg/m2; p < 0.0001), compared with placebo.*
• Subjects taking Adipromin had significant reductions in waist circumference (-2.12 inches vs. -0.67 inches; p < 0.0001) and hip circumference (-1.77 inches vs. -0.47 inches p < 0.0001) compared with placebo.*
• Subjects taking Adipromin had statistically significant improvement compared to placebo in their blood lipid profiles (p < 0.0001), including triglycerides.*
• Subjects taking Adipromin had improved serum adiponectin (p = 0.0071) and serum ghrelin (p = 0.0568) compared to those taking placebo.*
• Post-hoc analysis showed that subjects taking Adipromin had a more than 37% reduction in their Visceral Adiposity Index (VAI), whereas the VAI of those taking placebo increased slightly.

A third RCT, to be published in 2022, evaluated the impact of Adipromin on Resting Metabolic Rate (RMR) in healthy overweight subjects (n=60).4 By the end of the 7-day study, Adipromin supplementation had produced a significant increase in RMR compared to placebo (up to 15.2% higher), but with no stimulant effects, i.e., heart rate and blood pressure remained normal.* In fact, subjects felt better while burning more calories, as evidenced by a statistically significant improvement in their Profile of Mood States (POMS) scores compared to placebo.*

No other ingredient provides a comparable set of holistic benefits for weight management and cardiometabolic health:

• Fast results
o Significant weight loss in 14 days*
o Increased calorie burning in just 60 minutes*
• Support for long-term weight loss (steady results over a 4-month study)*
• Weight and inches reduction in both women and men*
• Targets fat while improving lean body mass*
• Significantly improved serum lipid profile*
• Improved biomarkers and beneficial impact on key metabolic proteins that govern adipogenesis, lipolysis, and the browning of white adipose tissue.*

Adipromin has been shown in preclinical and clinical studies to be safe and well-tolerated.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†These mechanisms of action for Adipromin were demonstrated in pre-clinical research, not in humans.